Failure of oral L-histidine to influence appetite or affect zinc metabolism in man: a double-blind study.

L-Histidine, 4 g/day in gelatin capsules, was administered orally to eight normal volunteers for 2 weeks in a double-blind, balanced, crossover study with 2 weeks of placebo treatment. Body weight, serum and urinary zinc and histidine concentrations, as well as subjective ratings of appetite, taste and smell perception, and food intake were monitored. L-Histidine therapy had no significant effect on appetite, taste and smell perception, food intake, or body weight. Similarly, no effects were observed on total serum zinc, albumin-bound zinc or alpha 2-macroglobulin-bound zinc concentrations, or on urinary histidine excretion. Serum histidine concentrations increased with therapy. Urinary zinc excretion was increased significantly after 1 week, but not after 2 weeks of L-histidine therapy. It can be concluded that oral L-histidine, at the dose used, has no value as an anorectic agent.

RCT Entities:   Population Interventions Outcomes